Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction
Crossref DOI link: https://doi.org/10.1007/s00280-015-2872-y
Published Online: 2015-10-23
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Deenen, Maarten J.
Meulendijks, Didier
Boot, Henk
Legdeur, Marie-Cecile J. C.
Beijnen, Jos H.
Schellens, Jan H. M.
Cats, Annemieke
Funding for this research was provided by:
Sanofi-aventis
Text and Data Mining valid from 2015-10-23